Germany's Merck KGaA said it will invest €40 million to build manufacturing and distribution centers in Asia to meet the growing demand for biopharmaceuticals.
The company will build manufacturing and distribution centers in South Korea's Incheon and India's Mumbai, which are expected to be fully operational by the end of 2019, Merck said in the news release.
The German life sciences and technology company's facility in China's Wuxi is expected to be ready in 2018 and will help meet the increasing biopharmaceutical demand in the country.
The investment follows Merck's €80 million investment in China's Nantong, announced in November 2016.
"Our investments in the important Asian markets of South Korea, India and China ensure that our customers have ready access to the products needed to develop new therapies and biosimilars that accelerate access to health for people everywhere," said Udit Batra, a member of Merck's executive board and CEO of the life science unit.